Dabrowski A, Ostrowska B, Bacior B, Fryśna-Dmuchowska B, Kargul W, Król J, Królikowski Z, Luczak D, Malczewska B, Nessler J
I Klinika Kardiologii IK Sl. AM w Katowicach.
Kardiol Pol. 1990 Mar;33(3):165-72.
The study was designed to assess the influences of antiarrhythmic therapy on exercise tolerance in patients with coronary artery disease and ventricular arrhythmias. Subjects for this study were subdivided into 3 groups: group I - 46 patients treated with amiodarone 1,200 mg daily during 10 days and 200-600 mg daily within next days, group II - 79 patients receiving disopyramide 300-600 mg daily, group III - 129 patients with combined administration of disopyramide 300-600 mg daily and propranolol 30-240 mg daily. propranolol 30-240 mg daily. Submaximal exercise stress testing was performed in each patient before treatment and after the medication for 4 weeks (group I) and for 2 weeks (groups II, III). The following parameters have been evaluated: maximal archived workload, maximal heart rate blood pressure response, double product (maximal heart rate x maximal systolic blood pressure), reasons for ending the test (target heart rate, typical angina, exhaustion, ST-segment depression greater than or equal to 2 mm, occurrence of ventricular arrhythmia, blood pressure greater than 250/120 mm Hg, significant drop in systolic pressure). Positive result of exercise ECG was defined: horizontal or down-sloping ST-segment depression greater than or equal to 1 mm and/or typical chest pain. The data from the first and second tests were estimated for significance of differences between the mean values with following results: 1) maximal achieved workload, 86 +/- 46 and 103 +/- 49 W (p less than 0.02) in group I; 101 +/- 64 and 106 +/- 50 W (NS) in group II; 107 +/- 55 and 119 +/- 54 W, W (p less than 0.01) in group III.(ABSTRACT TRUNCATED AT 250 WORDS)
该研究旨在评估抗心律失常治疗对冠心病合并室性心律失常患者运动耐量的影响。本研究的受试者被分为3组:第一组46例患者,先接受10天每天1200毫克胺碘酮治疗,之后每天200 - 600毫克;第二组79例患者,每天接受300 - 600毫克丙吡胺治疗;第三组129例患者,每天联合使用300 - 600毫克丙吡胺和30 - 240毫克普萘洛尔。在治疗前以及第一组用药4周、第二组和第三组用药2周后,对每位患者进行次极量运动应激测试。评估了以下参数:最大运动负荷、最大心率血压反应、双乘积(最大心率×最大收缩压)、测试结束原因(目标心率、典型心绞痛、疲劳、ST段压低≥2毫米、室性心律失常发生、血压>250/120毫米汞柱、收缩压显著下降)。运动心电图阳性结果定义为:水平或下斜型ST段压低≥1毫米和/或典型胸痛。对第一次和第二次测试的数据进行均值差异显著性评估,结果如下:1)第一组最大运动负荷分别为86±46瓦和103±49瓦(p<0.02);第二组为101±64瓦和106±50瓦(无显著性差异);第三组为107±55瓦和119±54瓦(p<0.01)。(摘要截短于250字)